558 results on '"Leppä, Sirpa"'
Search Results
2. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study
3. Inflammatory and subtype-dependent serum protein signatures predict survival beyond the ctDNA in aggressive B cell lymphomas
4. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
5. Proteomics uncovers molecular features for relapse risk stratification in patients with diffuse large B-cell lymphoma
6. Transformation and survival in marginal zone lymphoma: a Finnish nationwide population-based study
7. MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial
8. Gut microbiome-derived bacterial extracellular vesicles in patients with solid tumours
9. Blood Has Never Been Thicker: Cell-free DNA Fragmentomics in the Liquid Biopsy Toolbox of B-cell Lymphomas
10. Glofitamab monotherapy retreatment in patients with heavily pre-treated relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): Results from a phase I/II study.
11. Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma
12. Checkpoint protein expression in the tumor microenvironment defines the outcome of classical Hodgkin lymphoma patients
13. Elderly long-term survivors in the Nordic phase II study with first-line maintenance temozolomide for primary central nervous system lymphoma: a 10-year follow-up
14. Deep and Durable Responses with Epcoritamab SC Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma: Data from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort
15. Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma
16. Treatment response of colorectal cancer liver metastases to neoadjuvant or conversion therapy: a prospective multicentre follow-up study using MRI, diffusion-weighted imaging and 1H-MR spectroscopy compared with histology (subgroup in the RAXO trial)
17. Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma
18. Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis
19. Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series
20. Supplementary table S1 from Efficacy and Safety of Glycosphingolipid SSEA-4 Targeting CAR-T Cells in an Ovarian Carcinoma Model
21. Data from Efficacy and Safety of Glycosphingolipid SSEA-4 Targeting CAR-T Cells in an Ovarian Carcinoma Model
22. Supplementary Figure Legends from Efficacy and Safety of Glycosphingolipid SSEA-4 Targeting CAR-T Cells in an Ovarian Carcinoma Model
23. Supplementary Data S1. from Efficacy and Safety of Glycosphingolipid SSEA-4 Targeting CAR-T Cells in an Ovarian Carcinoma Model
24. Supplementary Figure S5 from Efficacy and Safety of Glycosphingolipid SSEA-4 Targeting CAR-T Cells in an Ovarian Carcinoma Model
25. Transformation and outcome of nodular lymphocyte predominant Hodgkin lymphoma: a Finnish Nationwide population-based study
26. Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes
27. IBCL-474 Epcoritamab + R2 Regimen and Responses in Patients With High-Risk Follicular Lymphoma, Regardless of POD24 Status
28. POSTER: IBCL-474 Epcoritamab + R2 Regimen and Responses in Patients With High-Risk Follicular Lymphoma, Regardless of POD24 Status
29. Intra-patient evolution of tumor microenvironment in the pathogenesis of treatment-naïve metastatic melanoma patients
30. S227: INITIAL SAFETY DATA FROM THE PHASE 3 POLAR BEAR TRIAL IN ELDERLY OR FRAIL PATIENTS WITH DIFFUSE LARGE CELL LYMPHOMA, COMPARING R-POLA-MINI-CHP AND R-MINI-CHOP
31. IBCL-460 Subcutaneous Epcoritamab With Rituximab + Lenalidomide (R2) in Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Update from Phase 1/2 Trial
32. Pixantrone beyond monotherapy: a review
33. Efficacy and safety of glycosphingolipid SSEA-4 targeting CAR-T cells in an ovarian carcinoma model
34. Characterization and clinical impact of the tumor microenvironment in post-transplant aggressive B-cell lymphomas
35. Drug screening approach combines epigenetic sensitization with immunochemotherapy in cancer
36. Supplementary Figure from Clinical Impact of Immune Cells and Their Spatial Interactions in Diffuse Large B-Cell Lymphoma Microenvironment
37. Supplementary Table from Clinical Impact of Immune Cells and Their Spatial Interactions in Diffuse Large B-Cell Lymphoma Microenvironment
38. Supplementary Data from Signal Transducers and Activators of Transcription 5a–Dependent Cross-talk between Follicular Lymphoma Cells and Tumor Microenvironment Characterizes a Group of Patients with Improved Outcome after R-CHOP
39. Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update
40. Survival, Transformation and Causes of Death of Follicular Lymphoma: A Finnish Nationwide Population-Based Study
41. Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase Ib-II Trial
42. Clinical findings of extranodal SNT lymphoid malignancies in a four-decade single-centre series
43. P115: Distinct signaling pathways and checkpoint molecule expression across histological subtypes of nodular lymphocyte-predominant Hodgkin lymphoma
44. T026: Characterization of cancer-associated fibroblasts in classical Hodgkin lymphoma
45. ABCL-340 Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase 2 Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume
46. Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase 2 Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume
47. Total peroxiredoxin expression is associated with survival in patients with follicular lymphoma
48. MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma
49. Low lymphocyte‐to‐monocyte ratio predicts poor outcome in high‐risk aggressive large B‐cell lymphoma
50. Subcutaneous epcoritamab with rituximab + lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.